Recent Updates
Recently added Catalysts
ACAD Positive Sentiment

Acadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026

Key Takeaway: Acadia Pharmaceuticals Inc. will report its second quarter 2026 financial results on August 4, 2026, after U.S. market close. The management team will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. This event will be accessible on Acadia's website and archived for 90 days.
Price reaction · baseline $25.92 (2026-07-15 close) · hit after-hours · clean, no other ACAD news in the window
day 0 close · peak
-1.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Acadia Pharmaceuticals is set to announce its financial results.
  • The announcement indicates ongoing business activity and transparency.
  • The conference call allows for direct engagement with investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+12%
120-day peak, hindsight
Typical move
5.6%
average across 7 past catalysts
Lead asset
Pimavanserin
Phase 2 · Agitation and Aggression in Alzheimer's Disease

Full Press Release Details

Company to host conference call and webcast onTuesday, August 4, 2026, at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on August 4, 2026, at 4:30 p.m. Eastern Time.
The conference call will be available on Acadia’s website,acadia.comunder the investors section and will be archived for approximately 90 days. The conference call may also be accessed by registering for the callhere. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals
Acadia is committed to turning scientific promise into meaningful innovation that makes the difference for underserved neurological and rare disease communities around the world. Our commercial portfolio includes the first and only FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome. We are developing the next wave of therapeutic advancements with a robust and diverse pipeline that includes mid- to late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. At Acadia, we’re here to be their difference. For more information, visit us atacadia.comand follow us onLinkedInandX.

Frequently Asked Questions

When will Acadia Pharmaceuticals announce Q2 2026 results?

Acadia Pharmaceuticals will announce its Q2 2026 results on August 4, 2026.

What time is the conference call for Q2 2026 results?

The conference call will take place at 4:30 p.m. Eastern Time on August 4, 2026.

Where can I access the conference call?

The conference call will be available on Acadia's website in the investors section.

How long will the conference call be archived?

The conference call will be archived for approximately 90 days.

Last updated: Jul 15, 2026